Articles by Laura Litwin
Dr. Osarogiagbon discussed the impact of the lung cancer screening program on diagnosis rates across the Mississippi Delta.
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Feldman presented on phase 2 patient-reported quality-of-life outcomes from the COCOON trial at the 2025 ASCO Annual Meeting.
The researchers explored the role of resilience in mediating the association between stigma and psychosocial adjustment.
The systematic review examined interventions for improving patient function at any stage or phase of lung cancer.
The phase 3 study compared the efficacy data of benmelstobart plus anlotinib with that of pembrolizumab monotherapy.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Malignant peritoneal mesothelioma is a rare disease with unspecific abdominal symptoms, often diagnosed at an advanced stage.
The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
The study examined the effectiveness of various interventions aimed at increasing lung cancer screening uptake rates.
Dr. Archambault discusses the safety and effectiveness of cemiplimab plus chemotherapy for first-line treatment of aNSCLC.
Dr. Conkling shared his research insights on PD-L1 testing practices for mNSCLC within US community oncology settings.
The forum covered critical updates in the fields of NSCLC, SCLC, immunotherapy effectiveness, and recent trial updates.
The panel discussed advancements in the field, including results from a study of lurbinectedin plus atezolizumab for SCLC.
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about oncology referrals in NSCLC.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about recent NSCLC innovations.
Sanjay Juneja, MD, directed a discussion with Dr. Liu, Dr. Das, and Dr. Singhi on key updates in the field of NSCLC.
Local therapy is recommended by NCCN guidelines, but how it is used in oligoprogressive disease is not well described.
The organization also granted priority review, breakthrough designation, and orphan drug designation to the application.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.